A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

@article{Ferrannini2013API,
  title={A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.},
  author={Ele Ferrannini and Leo J Seman and Elke Seewaldt-Becker and Stefan Hantel and Sabine Pinnetti and H. J. Woerle},
  journal={Diabetes, obesity & metabolism},
  year={2013},
  volume={15 8},
  pages={721-8}
}
AIM This Phase IIb, randomized, double-blind, placebo-controlled trial evaluated the efficacy, safety, tolerability and pharmacokinetics of empagliflozin in patients with type 2 diabetes. METHODS Four hundred and eight patients (treatment-naïve or after a 4-week wash-out period) were randomized to receive empagliflozin 5, 10 or 25 mg once daily, placebo or open-label metformin for 12 weeks. The primary endpoint was change in haemoglobin A1c (HbA1c) after 12 weeks. RESULTS After 12 weeks… CONTINUE READING